Interview with James Taylor of Precision NanoSystems
Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?
A: Patients are already receiving treatment using novel gene and cell therapies.
read moreInterview with Julie Eggington of Center for Genomic Interpretation
Q: Together with Robert Burton you founded the Center for Genomic Interpretation (CGI), a non-profit organization. Can you tell us more about CGI and the mission behind it?
A: CGI’s mission is to drive quality in clinical genetics and genomics. CGI works primarily with laboratories, health insurance payers, clinicians, and patients/consumers.
read moreInterview with Deven McGraw of Ciitizen
Q: Patient healthcare data aggregation and analysis is seen as both the panacea for tremendous breakthroughs in precision medicine and as one of its biggest challenges. Are both true and how so?
A:Yes, both are true. Achieving breakthroughs in precision medicine will require a lot of data – and yet it is often difficult for researchers to amass all of the data needed to advance precision medicine discoveries.
read moreBreaking News: CMS Takes Actions to Lower Prescription Drug and Other Healthcare Costs – Seema Verma Speaking @PMWC19
The cost of healthcare has been rising at an annual rate of 7% be it company-sponsored health insurance, public insurance such as Medicare and Medicaid, or private insurance. As such, healthcare was top of mind for many individuals this 2018. In the November midterm election many items related to healthcare such as Medicaid expansion, provider pay and indirect effects on the Affordable Care Act could be found on the ballot.
read moreDid You Catch All 6 of These Big Genomic Medicine Headlines in Recent Weeks?
Genomic sequencing, the driver of modern genomic medicine has come a long way in a short time, and its potential to continue driving innovations in precision medicine is enormous. PMWC 2019 Silicon Valley Jan. 20-23 in the Santa Clara Convention Center will focus on topics that are in the headlines and on everyone’s minds, in NGS and in precision medicine.
read moreInterview with Christopher Hopkins of NemaMetrix
Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?
A: We should all be working towards integrating these technologies into routine patient care as quickly as possible, because genomic medicine has the capacity to make profound impacts now.
read moreInterview with Kristine Ashcraft of YouScript
Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?
A: It’s certainly hard to predict, but our goal is to see precision medicine tools in the hands of most providers in the next five years.
read moreInterview with Laura Jelliffe-Pawlowski of UCSF
Q: Patient healthcare data aggregation and analysis is seen as both the panacea for tremendous breakthroughs in precision medicine and as one of its biggest challenges. Are both true and how so?
A: Dr. Jelliffe-Pawlowski: In my view, both are absolutely true – patient healthcare data aggregation allows for great breakthroughs and is also challenging from an ethical perspective in terms of privacy and patient choice.
read moreInterview with Dawn Barry of LunaDNA
Q: We have a long way to go with clinical trials participation. The enrollment number today is at 2-3% and that number is falling. What type and level of shift in culture, laws, collection methods, or other areas is going to be needed to accomplish widespread data sharing?
A: The old way of engaging with clinical trial participants needs to evolve into a model that is more collaborative and participatory.
read moreInterview with Dr. Richard Wender of American Cancer Society
Q: You recently recommended that colorectal cancer screening begin at age 45. How artificial intelligence and machine learning technologies might help better screen for cancer among different racial subgroups?
A: Assessing risk for CRC and screening status through EMR’s has traditionally been very difficult.
read more
